Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11221165 | 0.90 | LMNA (0.33) | TSHRLMNA | |
| SCHEMBL17464890 | 0.84 | TSHR (0.34) | TSHRLMNA | |
| SCHEMBL1874819 | 0.79 | FDPS (0.32) | TSHRLMNA | |
| SCHEMBL12187328 | 0.78 | TSHR (0.48) | TSHR | |
| SCHEMBL16074672 | 0.77 | TSHR (0.36) | TSHRLMNA | |
| Ammonia Solution, Strong SCHEMBL1334079 | 0.77 | FDPS (0.31) | TSHRLMNA | |
| SCHEMBL29155561 | 0.76 | TSHR (0.38) | TSHRLMNA | |
| SCHEMBL17467969 | 0.75 | DPP4 (0.33) | — | |
| SCHEMBL715079 | 0.75 | — | — | |
| SCHEMBL713526 | 0.74 | TSHR (0.38) | TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2569324-B1 | AMINOGLYCOSIDE DERIVATIVES | REMPEX PHARMACEUTICALS INC (US) | 2017-12-06 | — | — | EP | disclosed |
| US-20170298058-A1 | HETEROCYCLIC RING AND CARBOCYCLIC DERIVATIVE | SHIONOGI & CO (JP) | 2017-10-19 | — | — | US | disclosed |
| US-9550763-B2 | Heterocyclic ring and carbocyclic derivative | SHIONOGI & CO., LTD. (JP) | 2017-01-24 | — | — | US | disclosed |
| US-20160024072-A1 | Heterocyclic Ring and Carbocyclic Derivative | SHIONOGI & CO., LTD. (JP) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298058-A1 | HETEROCYCLIC RING AND CARBOCYCLIC DERIVATIVE | P2RX3, P2RX7, P2RX2 | TSHR 737/4885LMNA 3635/4885 |
| US-20160024072-A1 | Heterocyclic Ring and Carbocyclic Derivative | P2RX3, P2RX7, P2RX2 | TSHR 737/4885LMNA 3635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.